Login to Your Account

Exscientia's AI platform draws GSK in 10-compound discovery deal

By Nuala Moran
Staff Writer

Wednesday, July 5, 2017

LONDON – Glaxosmithkline plc has become the latest pharma to buy into artificial intelligence as a means to increase productivity in discovery, signing a £33 million contract under which Exscientia Ltd. will apply its technology to design 10 preclinical candidates.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription